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ABSTRACT: 
 
Beta-catenin is an essential cell adhesion and signaling protein, associated with 
high prolactin levels in rat pituitary tumor cells.  It has been shown that phosphorylation 
affects the location and activity of b-catenin.  Glycogen synthase kinase (GSK3-b) is a 
serine-threonine kinase that phosphorylates b-catenin on N-terminal residues, targeting it 
for proteasomal degradation.  Studies have shown that C-terminal tyrosine 
phosphorylation decreases the association of b-catenin with cadherin.  In 235-1 rat 
pituitary tumor cells, our lab has shown that the glucocorticoid analog dexamethasone 
(Dex) decreases the half- life of b-catenin while increasing the activity of GSK3-b .  The 
current study was undertaken to examine whether active GSK3-b  is necessary for the 
regulation of b-catenin in Dex-treated cells.  Duplicate cultures of 235-1 cells were 
grown for four days in the presence of 100 nM Dex.  To inhibit the activity of GSK3-b , 
control and Dex-treated cells were treated with 20 mM LiCl, a known inhibitor of GSK3-
b  activity.  Cell lysates were collected and analyzed by Western blotting.  
Phosphorylation-specific antibodies were used to detect levels of phosphorylated b-
catenin (Ser 33/37/Thr 41) and (Ser 45/Thr41), active GSK3-b  (Tyr 216) and inactive 
GSK3-b  (Ser 9).  Additional experiments examined tyrosine phosphorylated b-catenin 
through immunoprecipitation us ing a phosphotyrosine specific antibody, and by using a 
LAR tyrosine phosphatase which removes phosphates from ß-catenin.  Using l-
phosphatase, phosphates were removed nonspecifically from Ser, Thr, and Tyr residues 
in b-catenin to evaluate total phosphorylation.   After four days of treatment with Dex, b-
catenin levels were reduced by approximately 50%.  Levels of active GSK3-b  (Tyr 216) 
were increased in Dex-treated cells and levels of inhibited GSK3-ß (Ser 9) were 
decreased in Dex-treated cells.  This shows that Dex treatment alters activation of GSK3-
ß and likely functions in the regulation of b-catenin in 235-1 cells.  Tyrosine C-terminal 
phosphorylation of ß-catenin leads to a loss of cell- to-cell adhesion, which would lead to 
morphological changes.  Microscopic examination of Dex-treated cells showed the 
presence of more rounded cells than control cells.  Therefore, phosphorylation studies 
were conducted to examine changes in tyrosine C-terminal phosphorylation.  These 
studies demonstrated no detectable alterations in tyrosine C-terminal phosphorylation; 
however, the changes in cellular morphology suggest a loss of the cadherin-catenin 
adhesion complex in Dex-treated cells.  In Dex-treated cells l-Phosphatase removed 
phosphates in one major step.  However, in control cells an additional step was needed to 
remove phosphates from b-catenin, indicating that there is an alteration in phosphorylated 
b-catenin in Dex-treated cells.  Dex-treated cells showed an increase in the amount of 
phosphorylated (Ser 45/Thr41 and Ser33/37/Thr41) ß-catenin.  After a 24 hour treatment 
with LiCl, there was a decrease in the amount of Ser33/37/Thr41 phosphorylated ß-
catenin.  Phosphorylation on Ser 45 was still present after treatment with LiCl indicating 
that two separate kinases phosphorylate ß-catenin.  Furthermore, ß-catenin levels were 
restored, even though there was no apparent change in the level of active GSK3- b  .  These 
data suggest that the presence of Dex caused an increase in the degradation rate of b-
catenin by stimulating GSK3-b  activity.  Supported by NSF grant #IBN-9810327 to 
BCD. 
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INTRODUCTION: 
 
 Animals are composed of cells organized specifically to perform certain 
functions.  In order for an animal to function properly, their cells rely on constant, 
carefully orchestrated communication with each other, allowing homeostasis.  Cellular 
regulation is accomplished through both hormonal or electrical mechanisms and direct 
cell-to-cell contact.  Together, these processes allow animals to balance the needs of 
several body organ systems at one time. 
The Pituitary 
 The pituitary is an endocrine gland, which secretes hormones directly into the 
blood stream.  Located at the base of the brain, the pituitary is fully enc losed within the 
skull (Figure 1A).  The pituitary rests on the sella turcica, which is a depression in the 
cranial sphenoid bone, and it is divided into two lobes: the anterior pituitary and the 
posterior pituitary (Netter and Hansen, 2003) (Figure 1B).  The posterior pituitary serves 
a neurocrine function and releases two hormones: antidiuretic hormone (ADH) and 
oxytocin.  ADH helps the body regulate water, while oxytocin plays a role in uterine 
contraction during childbirth and allows contraction of milk glands for lactation.  
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Figure 1:  (A) Location of the pituitary gland: below the cerebrum and resting on 
bone.  (B)  The division of the pituitary into the two different lobes: anterior 
pituitary and posterior pituitary.   
 
 The anterior pituitary is an endocrine gland containing three different types of 
cells, which are classified according to the staining characteristics of their granules: 
basophils, chromophobes and acidophils (Cotran et al., 1999) (Figure 2).  The basophils 
take up basic stain; therefore, their granules stain blue.  The basophils comprise two types 
of endocrine cells: the gonadotrophs and the thyrotrophs.  The gonadotrophs secrete 
luteinizing hormone (LH) and follicle stimulating hormone (FSH), which act upon 
reproductive systems in male and females.  The thyrotrophs secrete thyroid stimulating 
hormone (TSH), which stimulates the thyroid to produce thyroid hormone.  The 
chromophobes do not take up any dye and they represent one type of hormone-secreting 
cells, the corticotrophs.  These endocrine cells secrete adrenocorticotropic hormone 
(ACTH), which stimulates the adrenal cortex to secrete cortisol, important in helping the 
body respond to stress.  The acidophils are the most common cell type found in the 
anterior pituitary.  These cells take up an acidic stain causing their granules to appear 
pink.  The acidophils consist of three types of hormone-producing cells: the lactrotrophs 
Anterior 
Pituitary 
 
B 
Posterior 
Pituitary                 
Pituitary 
Gland 
A 
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somatotrophs and somatolactotrophs.  The lactrotrophs produce prolactin (PRL), which 
stimulates milk production in the mammary glands.  The somatotrophs secrete growth 
hormone (GH), which promotes growth in long bones (Cotran et al., 1999).  The 
somatolactotrophs can produce both GH and PRL.  One characteristic of the acidophils is 
that they can undergo phenotypic switching, depending on the physiological cond ition of 
the animal (Kineman et al., 1992) (Figure 3).   
 
  In mature female animals, the main stimulus to induce an increase in the 
lactrotrophic acidophil population is from the hormone estrogen (Wilson, 1998; Johnson 
et al., 1998).  This situation applies in pregnant and post-partum females who need 
prolactin to produce milk for lactation.  Furthermore, the balance is shifted toward the 
somatotrophs in young animals, which do not require high levels of prolactin, but must 
Basophils Chromophobes 
Acidophils 
LH/FSH TSH 
ACTH 
PRL GH 
Figure 2:  Three classes of anterior pituitary cells and the hormones produced 
by these cells.   
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have growth hormone for development.  Cortisol, a glucocorticoid produced by the 
adrenal cortex, is known to stimulate GH secretion while decreasing PRL levels.  As 
these cells switch phenotypes from the lactrotrophs and somatotrophs, they undergo a 
transition stage in which the cells have characteristics of both groups.  These cells are 
called the somatolactotrophs and they can produce both prolactin and growth hormone.    
 
 
 
      
 
 
 
 
 
 
 
 
 
Pituitary Regulation  
 A characteristic unique to the acidophils is that the lactotrophs are the only 
pituitary cell type under primary inhibitory control.  The lactotrophs are under tonic 
dopaminergic inhibition from the hypothalamus (Johnson et al., 1998; Porter et al., 1994).  
Dopamine is a catecholamine neurotransmitter found in the central nervous system.  
Somatotrophs 
PRL 
PRL and GH 
Lactotrophs 
Acidophils 
Somato-
lactotrophs 
GH Reproductive status 
Estrogen 
Growth status 
Glucocorticoid 
Figure 3:  Phenotypoic switching of acidophil populations.  Estrogen stimulates 
prolactin production in mature female animals, while glucocorticoid stimulates 
growth hormone in young animals.    
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When it is released into the hypophysial portal blood system which connects the 
hypothalamus to the pituitary gland, dopamine will inhibit prolactin secretion. 
Conversely, some normal physiological conditions will stimulate prolactin secretion.  
Prolactin-releasing stimuli, such as nursing, will inhibit dopamine release from the 
hypothalamus, allowing pla sma levels of prolactin to rise, permitting milk production in 
the mammary glands.   
The adrenal glands, located at the superior pole of each kidney, also function in 
the regulation of the pituitary.  The adrenals produce the three classes of corticoidsteroids: 
the mineralocorticoids, gonadocorticoids and glucocorticoids.  Glucocorticoids are 
essential for life, as they prepare an individual for stress by suppressing inflammation, 
breaking down muscle to amino acids, converting amino acids and glycogen to glucose 
and promoting fat metabolism.  In the immune system they likewise serve as an 
immunosuppressant (Cotran et al., 1999; Andreoli et al., 1997).  
The most biologically active glucocorticoid is cortisol, which is a natural inhibitor 
of prolactin secretion (Figure 4).  Cortisol is secreted by the adrenals in response to 
ACTH, which is produced by the corticotrophs.  The presence of high levels of cortisol 
can inhibit the corticotrophs, thus decreasing the amount of ACTH secreted through an 
inhibitory feedback loop.  Without the ACTH stimulation, the adrenals over time will 
stop producing cortisol. 
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Pituitary Adenomas 
Prolactin secreting pituitary adenomas are the most common type of pituitary 
tumor, which produce and secrete excess levels of prolactin (Hardman et al., 2003).  
Controlling the growth of these tumors has been of clinical interest for some time due to 
the mass effect of the tumor itself and the problems associated with high prolactin levels 
in the bloodstream.  The space inside the skull is limited and an increase in the size of the 
pituitary can compress structures such as the optic nerve or cerebral blood vessels which 
result in loss of vision or ischemia to parts of the brain.  High prolactin levels in the 
Cortisol 
   Prolactin 
and ACTH 
Growth 
Hormone ACTH 
Adrenal cortex 
Dopamine 
from the  
hypothalamus 
Prolactin 
 
Figure 4:  Normal inhibition and control of PRL and GH secretion from the anterior 
pituitary.  
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bloodstream can result in infertility and changes in menstruation in women and cause 
impotence and gynecomastia in men.   
The treatment options for prolactinomas are very limited.  The primary regulation 
of prolactin secretion is from dopamine secreted from the hypothalamus (Porter et al., 
1994). Therefore, the first line of treatment for pituitary tumors is through dopaminergic 
drugs, such as bromocriptine, which decrease prolactin levels and lowers the growth rate 
(Hardman et al., 2003).  However, some pituitary tumors are not responsive to dopamine 
and, therefore, more invasive procedures including radiation or surgery must be 
implemented to remove the tumors.  In some cases, these are still ineffective in reducing 
hyperprolactinemia.  Thus, finding additional means to treat dopamine resistant tumors is 
of interest.    
Dexamethasone  
Our laboratory and others have found that the synthetic glucocorticoid analog 
dexamethasone (Dex) (Figure 5) inhibits prolactin levels (Spangler and Delidow 1998; 
Sakai et al., 1988).  This effect is not unexpected because it is part of the normal pituitary 
inhibition, where by cortisol hinders the lactotrophs from secreting PRL while 
stimulating the somatotrophs to secrete GH (Figure 4).  Naturally-occurring cortisone is 
produced from methylation of the fourth ring on cortisol.  However, the body must 
convert cortisone back to active cortisol, which is used by body systems to perform 
particular functions such as stimulating gluconeogenesis, or inhibiting prolactin levels 
and stimulating growth hormone.   Dexamethasone is a fluorinated analogue of cortisone 
and in our laboratory it was used instead of cortisol because Dex has a biological half- life 
of 36-54 hours, while cortisol has a half- life of 8-12 hours.     
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235-1 Rat Pituitary Tumor Cells 
The 235-1 cell line are rat pituitary acidophilic tumor cells, producing prolactin 
only.  These cells are a pure clone of lactotrophs and contain no somatotrophs: therefore, 
these cells are unable to produce growth hormone (Delidow et al., 1992; Billis et al., 
1992).  Previous work in our laboratory has shown that Dex inhibits cellular division in 
the 235-1 cells by blocking late G1 stage of the cell cycle, while simultaneously 
decreasing prolactin levels and decreasing cellular adhesion (Delidow et al., 2002). 
Cellular Adhesion    
 In the 235-1 cells, prolactin levels are directly related to cellular adhesion.  Cell-
to-cell adhesion is established by the catenin-cadherin complex, which is involved in 
signaling during embryonic development and in the maintenance and function of 
epithelial cell layers (Kemler, 1993; Papkoff, 1996; Hirano et al., 1992; Oyama et al., 
1994) (Figure 6).  
        Cortisol         Cortisone           Dexamethasone  
 
Figure 5:  Structure for cortisol the most biological active glucocorticoid.   
Cortisone is formed from methylating the fourth ring and then dexamethasone is 
a synthetic cortisone analogue.   
O
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Figure 6:  Diagram of the cadherin-catenin adhesion complex.  This is a homophilic 
interaction that occurs between two cells.  ß-catenin provides linkage of a-catenin to 
cadherin.     
 
 The cadherin-catenin adhesion complex mediates the homophilic interaction 
occurring between cells at the adherens junction.  Cadherin is a calcium dependent 
adhesion glycoprotein, containing three domains:  the extracellular cadherin repeats, a 
transmembrane region, and a cytoplasmic tail.  The extracellular cadherin repeats allow 
communication with other cells.  The cytoplasmic domain interacts with linker proteins 
including a-, ß- and g-catenin (Aberle et al., 1996).  The interactions between linker 
proteins are necessary for establishing a connection between the adhesion complex and 
the actin cytoskeleton.  The linker proteins may undergo phosphorylation, which results 
in the reduction or loss of cell- to-cell adhesion (Ohsugi et al., 1999).  Research in our 
laboratory has implicated dexamethasone (Dex) in reducing prolactin gene expression 
while simultaneously altering cadherin function through the regulation of b-catenin 
(Spangler and Delidow, 1998).   
 
a-catenin 
 
a-catenin ß-catenin 
ß-catenin Cadherin 
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Wnt Signaling     
 Beta-catenin is a multifunctional protein involved in both the cadherin adhesion 
complex and the Wnt signaling pathway (Figure 8).  ß-catenin’s structure contains three 
main domains :  the N-terminus, armadillo repeats, and the C-terminus (Figure 7).  The N-
terminus can become phosphorylated to regulate the degradation of ß-catenin, while the 
C-terminus is involved in association with cadherin.  There are eleven positively charged 
armadillo repeats found in ß-catenin’s structure.  These repeats aid in the binding of 
ligands such as a-catenin and cadherin, and they are used in recognition by the tumor 
suppressor protein adenomatous polyposis coli (APC) which aids in the degradation of ß-
catenin.   
 
Figure 7:  Structure of ß-catenin showing the N and C terminus and the armadillo 
repeats which are found in the center of the primary structure.  The colored boxes 
indicate the eleven positively charges armadillo repeat units.    
 
In the adhesion complex, ß-catenin provides the linkage of cadherin to a-
catenin and the actin cytoskeleton.  Cell-to-cell adhesion is dependent on the C-
terminal phosphorylation state of b-catenin.  In the absence of phosphorylation, the 
armadillo repeats of ß-catenin can interact with its C-terminal tail or with E-
cadherin.  E-cadherin and the b-catenin armadillo repeats interact electrostatically, 
 C N 
Armadillo Repeats 
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due to the acidic residues in cadherin and the positively charged groove in the 
armadillo repeats.  When b-catenin is phosphorylated at Tyr 654, the resulting steric 
hindrance forces the loss of binding to E-cadherin (Piedra et al., 2001; Takeda et al., 
1995; Hoschuetzky et al., 1994) (Figure 10).  In this case, ß-catenin dissociates from 
the adhesion complex and can undergo either translocation to the nucleus or rapid 
degradation.   In the presence of Wnt signaling, secreted Wnt glycoproteins bind to 
the Frizzled receptor.  The signal is transduced through a cytoplasmic protein 
cascade. First, the binding to the Frizzled receptor activates Dishevelled, which 
inhibits glycogen synthase kinase (GSK3-ß) from phosphorylating ß-catenin (Miller 
et al., 1999).  Absence of this phosphorylation inhibits the formation of the 
degradation complex of ß-catenin with axin, APC and GSK3-ß (Figure 8).  
Ultimately activation of Wnt signaling, allows ß-catenin to be translocated to the 
nucleus where it binds to T-cell factor (TCF-1), which then stimulates gene 
transcription and cell proliferation (Amit, et al., 2002; Chunming, et al., 2002) 
Glycogen Synthase Kinase 
 Glycogen Synthase Kinase (GSK3-ß) is a ubiquitously expressed 
serine/threonine protein kinase.  GSK3-ß participates in energy metabolism, regulating 
glycogen synthesis in response to insulin (Welsh et al., 1996).  GSK3-ß is involved in 
neuronal cell development and plays a role in Alzheimer’s disease through the hyper-
phosphorylation of Tau protein, which leads to formation of amyloid plaques (Phiel et al., 
2003).  Lastly, GSK3-ß is involved in the Wnt signaling pathway.  In this pathway 
GSK3-ß plays an important role in regulating ß-catenin.  In the absence of Wnt signaling, 
GSK phosphorylates ß-catenin.   Once phosphorylated, ß-catenin forms a complex with 
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adenomatous polyposis coli (APC) and axin, which targets the protein for proteasomal 
degradation (Figure 8).  
 
Figure 8:  Diagram of Wnt signaling.  The figure illustrates the pathway ß-catenin 
undergoes in the presence or absence of Wnt signaling.  In the presence of Wnt 
signaling ß-catenin is translocated to the nucleus where it binds to TCF to initiate 
gene transcription.  In the absence of Wnt ß-catenin is phosphorylated by GSK3-ß 
and targeted for proteasomal degradation.  Illustration provided by S. Fish 
Department of Anatomy, Cell and Neurobiology, Marshall University School of 
Medicine. 
 
 
ß-catenin Phosphorylation Sites   
 N-terminal phosphorylation is important for b-catenin regulation by the Wnt 
signaling pathway, which takes place through the following mechanism:  Casein kinase 
(CK1) phosphorylates b-catenin on Ser 45, by a non-Wnt related signaling pathway, thus 
priming b-catenin for further phosphorylation (Provost et al., 2003).  In the absence of 
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Wnt signaling, GSK3-ß targets ß-catenin for proteasomal degradation by phosphorylating 
additional N-terminal (Ser 33/37 and Thr 41) sites (Figure 9).  The CK1 phosphorylation 
site (Ser 45) and the GSK3-ß targeted sites are conserved from Drosophila to humans.  
Mutations in the N-terminal phosphorylation sites of b-catenin results in protein 
stabilization, which can lead to tumorigenesis.  Mutating Ser 45 results in a loss of the 
priming phosphorylation on ß-catenin.  This results in a reduction of the ability of GSK3-
b  to phosphorylate ß-catenin, which then leads to a decrease in the degradation of b-
catenin (Provost et al., 2003).  
 
Figure 9:  Diagram of phosphorylation sites on ß-catenin.  C-terminal Tyr 654 
phosphorylation releases ß-catenin from the adhesion complex.  The N-terminal 
phosphorylation sites are involved in degradation of the protein.  Ser 45 is a priming 
site and allows ß-catenin to be further phosphorylated on Ser 33/37/Thr41 which 
targets the protein for proteasomal degradation.    
 
Our lab has previously shown that treatment of 235-1 rat pituitary cells with  
100 nM Dex causes a 50% reduction in the levels of ß-catenin by altering its half- life.  
Current research has shown global reduction in nuclear, cytoplasmic and membrane- 
bound ß-catenin.  There is no change in the level of total GSK3-ß, which suggests that 
there is an alteration in the amount of active GSK3-ß enzyme in Dex-treated cells.  In the 
N C Armadillo Repeats 
Ser 33, 37,  
Thr 41 
Ser 45 
CK1 
Tyr 654 
GSK3-b 
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current study, phosphorylation-specific antibodies were used to detect the amount of 
active GSK3-b  (Tyr 216) enzyme and changes in the inhibitory phosphorylation of 
GSK3-ß (Ser 9).  Lithium, a known inhibitor of the GSK3 family of protein kinases 
(Stambolic, et al., 1996) was used to determine the effect of blocking GSK3-b  enzyme 
activity on ß-catenin protein levels.  It is believed that glucocorticoid treated 235-1 cells 
regulate ß-catenin levels by increasing the activity of GSK3-ß.  Because phosphorylation 
leads to the degradation of ß-catenin, phosphospecific antibodies (Ser 33/37/Thr41 and 
Ser 45/Thr41) were used to examine the effects of Dex on the phosphorylation state of ß-
catenin.  If active GSK3-ß is increased in glucocorticoid- treated cells, it is also expected 
that there will be an increase in the amount of phosphorylated forms of ß-catenin, since 
these sites regulate the degradation of the protein.  Additional experiments examined total 
phosphorylation sites on ß-catenin in order to determine the effect of Dex on the Ser, Thr 
and Tyr phosphorylation. 
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Methods: 
 
Cell Culture  
 The 235-1 rat pituitary cells were maintained in tissue culture flasks in DMEM-
high glucose media (Life Technologies), containing 10% iron-supplemented bovine calf 
serum (Hyclone), 10 mM HEPES (pH 7.4), 100 U/mL of penicillin, 100 µg/mL of 
streptomycin and 5 µg/mL of plasmocin (InvivoGen).  Cells were split 1:20 once weekly 
in phosphate buffered saline (PBS) containing 0.5 mM EDTA 
(ethylenediaminetetraacetic acid, PBS, pH 7.4) then seeded onto 100 mm culture dishes 
(Falcon).  Cells were grown for a 24 hour period before the beginning of each experiment 
to allow for attachment and growth.   
A 1 mM stock solution of Dex (Sigma) was prepared in ethanol.  A 100 µM 
working solution of Dex was made by dilution in sterile PBS.  Cells were treated with 
100 nM Dex or vehicle (10 µL of 10% ethanol in PBS) for a period of four days.  The 
cells were fed and treated every two days for the duration of the experiment.  In certain 
experiments, duplicate cultures of control and Dex cells were treated with 20 mM LiCl 
for 24 hours prior to cell collection.  Cells were collected on day five by scraping; 
washed once in 1 mL of PBS; then lysed and analyzed as described.   
 
Sample Preparation 
 Cell pellets were lysed by sonication using the Tekmar Sonic Distruptor.  Cells 
were suspended in two pellet volumes (up to 180 µL) HEPES/NP-40 lysis buffer (10 mM 
HEPES pH 7.5, 150 mM NaCl, 1.5 mM EDTA and 1% NP-40) containing protease 
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inhibitor cocktail (Sigma: AEBSF, Aprotinin, Leupeptin, Bestatin, Pepstatin A, E-64).  
The sonicator was set to an output of 45 Hz and the samples were sonicated 3X for five-
second bursts.  The phosphospecific experiments included phosphatase inhibitor cocktails 
1 (Sigma: cantharidin, bromotetramisole, microcystin LR) and cocktail 2 (Sigma: sodium 
orthovanadate, sodium molybdate, sodium tartrate, imidazole) in the lysis buffer.  Lysates 
were cleared by centrifugation.  The bicinchoninic acid (BCA) assay (Pierce) was then 
employed to determine protein concentration.  In this assay proteins interact with Cu2+,  
forming Cu1+, and this in turn interacts with the BCA compound  forming a purple color 
that can be measured at an absorbance of 562 nm.  
 
Electrophoresis and Transfer 
 Aliquots of 30-50 µg of protein were added to 2X SDS sample buffer (0.046% 
SDS, 10% b-mercaptoethanol, 20% glycerol, 0.0125 M Tris, pH 6.8, 0.01% bromophenol 
blue) and samples were separated by 10% SDS-PAGE in running buffer at 125 V for one 
hour.  Samples were then electroblotted onto nitrocellulose (Osmonics) in transfer buffer 
at 100 V for one hour.   
 
Western Blotting 
All experiments analyzed by Western blotting were performed according to the 
manufacturers’s protocols with antibodies against the protein of interest (b-catenin, 
Sigma; GSK3-b , Biosource International; Phospho-GSK3-b  (Ser 9), Cell Signaling; 
Phospho-b-catenin (Ser 45/Thr 41) and (Ser33/35 Thr41), Cell Signaling; Phospho-
tyrosine (PY-20), Transduction Laboratories). The non-phosphospecific blots were 
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blocked with 5% nonfat dried milk (Carnation) in TBST (10 mM Tris, pH 8.0; 150 mM 
NaCl; 0.1% Tween-20) for one hour at room temperature with gentle agitation.  
Phosphospecific antibodies were used at a 1:1000 dilution according to manufacturer 
recommendations, in 5% Bovine Serum Albumin (BSA) in TBST at 4°C overnight.  
Blots were washed three times (5 minutes each) in TBST and then incubated for an hour 
at room temperature with the appropriate peroxidase- labeled secondary antibody (1:3000 
in 5% milk with TBST) (Vector Labs).  All additional antibodies (b-catenin and GSK3-b) 
were blocked and incubated with a primary antibody dilution ranging from 1:4000 to 
1:5000 in 3-5% milk in TBST; the horseradish peroxidase (HRP)-conjugated secondary 
antibody was diluted 1:3000 in the same buffer.  Signals were detected using enhanced 
chemiluminescence (SuperSignal reagent, Pierce) and exposed on to x-ray film. Blots 
were analyzed by the Personal Densitometer, using Image Quant software (Molecular 
Dynamics). 
 
Phosphatase Treatment of Cellular Extracts 
 Aliquots of 100 µg of protein collected from control and Dex-treated cultures 
were incubated with l phosphatase buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.1 
mM MnCl2, 0.1 mM EGTA, 2 mM dithiothreitol, 0.01 Brij 35 and 50% glycerol) and 400 
U of l phosphatase (New England Biolabs) in a reaction volume of 20 µL.  The samples 
were incubated at 30°C for 0-30 minutes.  Samples then were mixed with an equal 
volume of SDS sample buffer, denatured at 100°C and resolved on a 7.5% 
polyacrylamide gel.  Samples were transferred to nitrocellulose and analyzed for b-
catenin by Western blotting.  
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LAR Protein Tyrosine Phosphatase 
 Aliquots of 50 µg of protein collected from control and Dex-treated cultures were 
incubated with LAR Buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.0, 2 mM Na2EDTA, 5 
mM dithiothreitol, 0.01 Brij 35, 50% glycerol and purified 10 mg/ml of BSA) and  5 U of 
LAR Protein Tyrosine Phosphatase (New England Biolabs) in reaction volume of 20 µL.  
The samples were incubated at 30°C for 0-30 minutes.  Samples then were mixed with an 
equal volume of SDS sample buffer, denatured at 100°C and resolved on a 7.5% 
polyacrylamide gel.  Samples were transferred to nitrocellulose and analyzed for b-
catenin by Western blotting.  
 
Subcellular Fractionation 
 Control and Dex-treated samples were collected and washed with PBS to remove 
any extra media from the cells.  Five pellet volumes (up to 500 µL) of hypotonic lysis 
buffer ( 20 mmol/L HEPES pH 7.5, 10 mM potassium acetate, 1.5 mM magnesium 
acetate) was added to the cellular pellet.  The cells were dounce homogenized (rubbed 
against ground glass) for a total of 10 strokes.  Samples were then subjected to low speed 
centrifugation (approximately 2,000 rpms) for five minutes.  After reserving the 
supernatant, the pellet was resuspended in two pellet volumes (100 µL) hypotonic lysis 
buffer and again subjected to low speed centrifugation two more times, with reserving the 
supernatant each time.  The nuclear pellet was resuspended in 1% NP-40 in PBS also 
containing protease inhibitor cocktail.  The pooled supernatant was centrifuged at 4 °C 
for 1 hour at 13,000 rpms.  The pellet containing the membrane fraction was resuspended 
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in 1% NP-40 in PBS containing protease inhibitor cocktail.  The supernatant represented 
the cytoplasmic fraction.            
 
Immunoprecipitation and Detection of Tyrosine Phosphorylation 
 Aliquots of 250 mg of protein were precleared by incubation with 0.5 mL of 
normal mouse IgG (Sigma) and 20 mL protein G-agarose (Oncogene Research Products) 
for 30 minutes at 30°C.  The samples were subjected to centrifugation at 2,500 rpms for 5 
minutes at 4°C.  The supernatant was transferred to a new tube with 2 mg of b-catenin 
antibody (Tranduction Laboratories) and incubated for one hour at 4°C.   Protein G 
agarose beads (20 mL) were added to the tubes and incubated overnight at 4°C.  The 
samples then were cleared by centrifugation (2,500 rpms) for five minutes at 4°C and   
the pellets were washed four times with 100 mL of lysis buffer containing 100 nM 
vanadate (pH 7.4).  The pellet then was resuspended in 20 µL 2X SDS-PAGE sample 
buffer.  The samples were denatured and 10 µL of the samples were resolved on a 10% 
polyacrylamide gel, transferred to nitrocellulose and analyzed for tyrosine 
phosphorylation by immunoblotting.  
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RESULTS: 
To determine the mechanism by which glucocorticoid acts to alter the levels of ß-
catenin in 235-1 cells, replicate cultures of 235-1 cells were treated with 100 nM Dex for 
a period of either two or four days.  Cells were collected, lysed and BCA analysis was 
employed to determine protein concentration.  Previous work demonstrated there is no 
change in the mRNA levels of ß-catenin; therefore, we analyzed post-translational 
regulation by measuring the protein level of ß-catenin by Western blotting (Fig. 10).  In 
this and other repeated experiments, we found that Dex causes a 50% decrease in the 
expression of ß-catenin.  Because previous work showed no alternation in ß-catenin 
mRNA levels in Dex-treated cells, half- life studies were conducted to determine the 
degradation rate of ß-catenin (Jones, R. unpublished results).  Cells were treated with Dex 
for two days followed by cyclohexamide (CHX) for 120 minutes.  The samples were 
resolved on a polyacrylamide gel, transferred to nitrocellulose and then analyzed by 
Western Blotting.  This revealed a decrease in the half- life of ß-catenin from twenty 
minutes in control cells compared to nine minutes in Dex-treated cells.   
 
Figure 10:  Expression of ß-catenin in 235-1 cells, determined by Western blotting.  Duplicate 
cultures were isolated after four days from control or 100 nM Dex-treated cells.  Aliquots of protein 
(40 µg) were probed with antiserum against ß-catenin.  A representative blot is shown.  [Lanes 1 and 
2 control; lanes 3 and 4 Dex].  There is a 40% decrease in ß-catenin levels in Dex-treated cells.  
 
In glucocorticoid-treated cells, cellular morphology is altered such that the cells 
appear more rounded and have shorter processes than controls (Fig. 11A).  These 
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alterations suggested a loss of cellular adhesion.  Dex causes a decline in the growth rate 
which is evident in Figure 11A, since we can see a decrease in cell numbers (Delidow et 
al., 2002).  Previous work in the lab also showed that treatment with Dex results in a 50% 
reduction in the re-aggregation of cells (Spangler and Delidow, 1998).  Phosphorylation 
of Tyr 654 decreases ß-catenin binding to the cadherin-catenin adhesion complex; 
therefore we examined changes in Tyr phosphorylation in both control and Dex-treated 
cells.  Duplicate cultures were treated for four days with Dex.  Figure 11B is a 
representative blot showing Tyr phosphorylated ß-catenin analyzed by 
immunopreciptating ß-catenin from 250 µg of cellular protein.  The blot was probed with 
an anti-Tyr antibody (PY-20).  This experiment revealed no changes in Tyr 
phosphoryla ted ß-catenin, even though changes in cellular morphology were evident (Fig 
11A).  Figure 11C is a representative blot showing the removal of phosphates from 
tyrosine in ß-catenin.  Aliquots of protein (50 µg) were treated for 30 min with LAR 
tyrosine phosphatase, which served to remove phosphates from Tyr.  After gel 
electrophoresis (7.5%) and transfer, the blots were probed with an antibody against ß-
catenin.  By running this experiment on a low percentage gel, as the phosphates are 
removed there should be shifts in the protein bands due to loss of the phosphates since the 
molecular weight of ß-catenin is decreasing by approximately 80 Da each time a 
phosphate is removed.  As shown in Figure 11C, there are no shifts in the bands due to 
the loss of phosphates therefore there are no apparent alteration in Tyr phosphorylated ß-
catenin.  It is possible that the resolving power was not sufficient to detect the loss of 
phosphates.  This is because ß-catenin is not a highly Tyr phosphorylated protein.  There 
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are only three Tyr phosphorylated sites in the protein, therefore it may be hard to detect 
the shifts in molecular weight.    
A         Control          100 nM Dex                                                       
 
B 
 
C 
 
Figure 11:  (A) Morphological changes induced by addition of glucocorticoid.  Cells were treated 
with Vehicle or Dex for four days and images were taken at 100X magnification.  Dex-treated cells 
are more rounded and have shorter appendages.   (B) Analysis of Tyr 654 phosphorylated ß-catenin.  
Aliquots of protein lysates (250 mg) were immunoprecipitated with antiserum against b-catenin.  
Samples were then analyzed by Western blotting using a tyrosine specific antibody (PY-20).  A 
representative blot is shown.  [Lanes 1, 2, 5 and 6 control; lanes 3, 4, 7 and 8 Dex].  There are no 
observable changes in tyrosine phosphorylated b-catenin between the control and Dex-treated cells. 
(C)  Removal of phosphates from tyrosine phosphorylated ß-catenin.  Duplicate  cultures were 
analyzed by Western blots of protein isolated from control and 100 nM Dex-treated cells.  Aliquots of 
protein (50 mg) were treated for 30 min with LAR Tyrosine phosphatase, which served to remove all 
Tyr phosphate groups.  Samples were probed with antiserum against b-catenin and a representative 
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blot is shown.  [Lanes 1, 2 and 3 control samples; lanes 5, 6 and 7 represent Dex-treated cells at 
indicated time intervals].  There does not appear to be any difference in Tyr phosphorylated b-
catenin with glucocorticoid treatment. 
 
Beta-catenin is localized in three separate places within the cell.  We attempted to 
determine by subcellular fractionaltion whether glucocorticoid treatment causes any 
alterations in ß-catenin’s localization.  It is expected that Dex-treated cells will show a 
decrease in cytoplasmic ß-catenin due to the increased degradation rate of the protein.  
Using a cell fractionation extraction protocol, protein was isolated from the nucleus, 
cytoplasm and membrane.  The results in Figure 12 indicate that glucocorticoid treatment 
results in a decrease in cytoplasmic, nuclear and membrane-bound ß-catenin.  The 
greatest percentage decrease is shown in the nucleus and membrane.  The loss of any of 
the linker proteins (a- or ß-catenin) from the adhesion complex results in a decrease in 
cellular adhesion (Ohsugi et al., 1999).  In our cell line, glucocorticoid treatment reduces 
the amount of membrane bound ß-catenin.  This process alone can cause a reduction in 
cell-to-cell adhesion and this is evident in morphological changes that occur with 
glucocorticoid treatment (Spangler and Delidow, 1998) (Figure 11A).     
  
 
Figure 12:  Expression of total ß-catenin localization in 235-1 cells determined by Western blots of 
protein isolated from replicate cultures of control or 100 nM Dex-treated cells isolated from the 
cytoplasm, nucleus and membrane.  Cells were treated for two or four days and then collected.  
Aliquots of protein (40 µg) were examined using a specific antibody against ß-catenin.  A 
representative blot is shown.  ß-catenin levels were decreased in the cytoplasm, nucleus and 
membrane.  
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Cytoplasmic b-catenin is regulated by Wnt signaling and phosphorylation at key 
N-terminal sites.  To study the mechanism by which 235-1 cells regulate ß-catenin levels 
we examined GSK3-ß, a kinase that phosphorylates ß-catenin, leading to proteasomal 
degradation.  Since ß-catenin levels are reduced by 50% when 235-1 cells are treated 
with glucocorticoid, it might be expected that there is an increase in the amount of active 
kinase essential to the phosphorylation of ß-catenin.  We examined the levels of total 
GSK3-ß in both control and Dex-treated cells.  Duplicate cultures were treated with Dex 
for periods of two and four days.  As shown in Figure 13A, the levels of total GSK-ß 
remain unchanged after four days of treatment with Dex.    
In order to ascertain whether Dex treatment causes any alterations in the amount 
of active GSK3-ß we examined the protein levels of Tyr 216 phosphorylated GSK3-ß.  
This site is phosphorylated in active GSK3-ß (Figure 13B).  After a four day treatment 
with Dex, the amount of active GSK3-ß was increased two-fold.  When GSK3-ß is 
phosphorylated on Ser 9, the kinase activity is inhibited; therefore we wanted to note if 
there is any alteration in the inhibition of GSK3-ß in the presence of Dex (Fig 13C).  
When 235-1 cells are treated for a period of four days in the presence of Dex, we see a 
25% decrease in the amount of the Ser 9 phosphorylated inactive GSK3-ß.    Thus, 
treatment with glucocorticoid caused an increase in the amount of active Tyr 216 
phosphorylated GSK3-ß, and a decrease in the amount of inhibitory Ser 9 phosphorylated 
GSK3-ß.  Both suggest that the 235-1 cells regulate ß-catenin levels in the presence of 
Dex by increasing the activity of GSK3-ß.     
 25  
The levels of ß-catenin and GSK3-ß were then measured in the presence of LiCl, 
a known inhibitor for GSK3-ß enzymes.  When GSK3-ß activity is inhibited, ß-catenin 
will not be targeted for proteasomal degradation.  As shown in Figure 13D, 
glucocorticoid treatment results in a decrease in the amount of ß-catenin with a 
simultaneous increase in the amount of active GSK3-ß.  However, when LiCl is added to 
duplicate cultures of control and Dex-treated cells, active GSK3-ß is still present, but ß-
catenin levels are restored.  This suggests that while GSK3-ß can be activated in the 
presence of LiCl, it is unable to phosphorylate ß-catenin.   
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Figure 13:  (A) Expression of total GSK3 -b in 235-1 cells determined by Western blots of protein 
isolated from replicate cultures of control or 100 nM Dex-treated cells.  Cells were treated for two or 
four days and then collected.  Aliquots of protein (40 µg) were examined using a specific antibody 
against GSK3 -b.  A representative blot is shown.  [Lanes 1, 2 and 3 control; lanes 4, 5 and 6 Dex].  
The top Western blot represents a two day treatment with Dex, while the bottom Western blot 
represents a four day treatment with Dex.  The total level of GSK3 -b was not altered in control or 
Dex-treated cells; however, b-catenin levels are reduced by 40-50% in the Dex-treated cells.  (B) 
Expression of active GSK3 -b (Tyr 216) in 235-1 cells.  Samples were collected from duplicate cultures 
of control or 100 nM Dex-treated cells.  Cells were treated for four days and Western blots of protein 
were probed using a phosphospecific antibody against active GSK3 -b.  Aliquots of cellular protein 
(40 µg) were analyzed for active enzyme.  A representative blot is shown.  [Lanes 1 and 2 control; 
lanes 3 and 4 Dex].  The amount of active GSK3 -ß enzyme was doubled in Dex-treated cells; 
simultaneously, ß-catenin expression was decreased.  (C)  Expression of Ser 9 phosphorylated GSK3 -
b.  Western blots of protein (30 µg) isolated from the control or 100 nM Dex-treated cells were 
probed using a phosphospecific antibody for GSK3 -b (Ser 9), which is the inhibited form.  A 
representative blot is shown.  [Lanes 1, 2, 5 and 6 control; lanes 3, 4, 7 and 8 Dex].  Changes in 
inhibitory phosphorylation between control and treated cells are visible.  Dex-treated cells show a 
25% decrease in inhibitory Ser 9 phosphorylation, indicative of increased GSK3 -b  enzyme activity. 
(D) Expression of b-catenin and active GSK3 -b.  Duplicate cultures were analyzed by Western blots 
of protein isolated from control, 100 nM Dex, 20 mM LiCl or LiCl and Dex-treated cells. Control and 
Dex-treated cells were treated for four days and LiCl, which inhibits GSK3 -b activity, was added to 
cultures one day prior to cell collection.  Samples were probed using a phosphospecific antibody 
against GSK3 -b phosphorylated at Tyr 216 and antiserum against b-catenin.  Aliqu ots of protein (40 
µg) were analyzed for b-catenin and active GSK3 -b enzyme.  A representative blot is shown.  [Lanes 
1 and 2 control; lanes 3 and 4 Dex; lanes 5 and 6 LiCl; lanes 7 and 8 Dex and LiCl].  The top band 
represents b-catenin, while the bottom band represents the active GSK3 -b enzyme.  Active GSK3 -ß 
enzyme was increased in Dex-treated cells; the levels of ß-catenin were decreased   
 
 
Degradation of ß-catenin occurs by phosphoryla tion at key N-terminal residues, 
and this phosphorylation is the key regulator of cytoplasmic ß-catenin levels (Amit et al., 
2002; Chunming et al.,  2002; Provost et al., 2003).  Phosphorylation of ß-catenin was 
examined to determine the effects of glucocorticoid on the degradation of ß-catenin.  As 
shown in Figure 14A, total levels of phosphorylated ß-catenin were examined by using ?-
phosphatase, which removes phosphates nonspecifically from Ser, Thr and Tyr on ß-
catenin over the course of 30 minutes.  In both control and Dex-treated cells, phosphates 
were removed in one major dephosphorylation step, evident at 0 minutes.  However, 
control cells needed additional time to remove further phosphates, suggesting that 
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degradation of ß-catenin is occuring more rapidly in Dex-treated cells, as opposed to 
control cells. 
 In light of these results, we examined the specific N-terminal phosphorylation 
using phosphospecific antibodies.  In Figure 14B, we examined Ser 45 phosphorylated ß-
catenin.  In this experiment cells were treated for four days in the presence of Dex and 
then, on the third day, 20 mM LiCl was added to inhibit GSK3-ß activity.  The results 
show that glucocorticoid causes an increase in the amount of phosphorylated ß-catenin.  
Treatment with LiCl induced a slight decrease in the amount of phosphorylated ß-catenin.  
This is likely due to the specificity of the antibody, which recognizes a GSK3-ß targeted 
site, Thr 41, as well as the non-GSK3-ß site Ser 45.  We also examined the GSK3-ß 
targeted sites using a phosphospecific antibody that recognizes ß-catenin only when it is 
phosphorylated at Ser 33/37/Thr41 (Figure 14C).  These sites become phosphorylated 
only after ß-catenin is primed at Ser 45, by Casein Kinase 1.  The results from this 
experiment indicate that there is an increase in the amount of phosphorylated ß-catenin 
when cells are treated with Dex.  However, when LiCl is added to inhibit GSK3-ß 
activity, there is a dramatic decrease in the amount of Ser 33/37/Thr41 phosphorylated ß-
catenin.  Together these data suggest that ß-catenin levels are regulated in glucocorticoid-
treated cells by increasing the amount of phosphorylated ß-catenin.  These results also 
suggest that there are at least two different kinases that phosphorylate ß-catenin in 
response to glucocorticoid leading to degradation. 
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Figure 14:  (A) Expression of phosphorylated ß-catenin in 235-1 rat pituitary cells.  All samples were 
treated for four days; protein expression from control and (100 nM) Dex was analyzed by Western 
blot technique.  Treatment of lysates with l Phosphatase for 30 minutes served to remove all 
phosphate groups.  Samples were probed with antiserum against b-catenin.  Aliquots of 100 mg of 
protein were analyzed and a representative blot is shown.  [Lanes 1, 2 and 3 represent control 
samples at indicated time intervals.  [Lanes 4, 5 and 6 represent Dex treated cells]  The results show a 
change in the phosphorylation states of b-catenin in both control and Dex-treated cells.  l-
 30  
phosphatase removed phosphates in one major step in both control and Dex-treated cells.  Control 
cells needed additional time to remove phosphates, as evident from the b-catenin band shifts in lanes 
2 and 3.  The b-catenin still present on the film indicates remaining nonphosphorylated forms.  
(B) (C) Expression of phosphorylated b-catenin (Ser 45/Thr 41 and Ser33/37/Thr41).  Western blots 
of protein (40 mg) isolated from control, 100 nM Dex, 20 mM LiCl or Dex + LiCl-treated cells.  
Control and Dex-treated cells were treated for six days and LiCl was added to cultures one day prior 
to cell collection.  Immunoblots were probed using a phosphospecific b-catenin antibodies, which 
detects levels of b-catenin when phosphorylated at Ser 45/Thr41 or Ser 33/37/Thr41. Representative 
blots are shown.  [Lanes 1 and 2 control; 3 and 4 Dex; 5 and 6 LiCl; 7 and 8 Dex and LiCl].  In figure 
B, there is an increase in Ser 45/Thr 41 phosphorylated b-catenin in Dex-treated cells, regardless of 
the presence of LiCl. The mechanism of Ser 45 phosphorylation occurs by an alternate kinase, CK1, 
which primes b-catenin for further phosphorylation by GSK3 -b.  In figure C, there is an increase in 
Ser 33/37/Thr 41 phosphorylated b-catenin in Dex-treated cells.  In LiCl-treated cells, there is a 
decrease in phosphorylated b-catenin, as lithium functions to inhibit GSK3 -b activity.  
 
  
Previous work in our lab has shown that glucocorticoid treatment reduces 
prolactin gene expression and causes a decrease in cellular adhesion.  When 235-1 cells 
are treated with glucocorticoid, we see a simultaneous decrease in prolactin and ß-catenin 
levels.  We wanted to determine whether there exists a common pathway relating ß-
catenin and prolactin; therefore our experiments were designed to examine the effects of 
LiCl on prolactin protein levels (Figure 15 A B).  Cells were treated for a period of two 
or four days with Dex, and 20 mM LiCl for one day.  After two and four day treatment 
with glucocorticoid there is a decrease in prolactin levels.  Four-day control cells show an 
increase in prolactin levels, possibly due to the increase in cell-to-cell adhesion.  After 
four days of growth the cells are confluent and they have numerous contacts with each 
other.  In the 235-1 cell line if the contacts between cells are increased then prolactin 
levels will increase simultaneously.  Treatment with LiCl slightly decreased basal 
prolactin levels and did not alter the response to Dex.  One possible reason for the 
decrease in basal prolactin levels is because cells have been treated with Dex 
simultaneously, which is known to decrease prolactin gene expression and protein levels.  
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Treatment with LiCl for 24 hours may not be enough time to restore adhesion, which 
would ultimately increase prolactin levels in the 235-1 cells.   
A 
 
 B 
 
 
Figure 15:  Expression of prolactin in 235-1 cells.   Western blots of protein (40 mg) isolated from 
control, 100 nM Dex, 20 mM LiCl or Dex + LiCl-treated cells.  Control and Dex-treated cells were 
treated for two and four days and LiCl was added to cultures one day prior to cell collection.  
Immunoblots were probed using antisera against prolactin.  A representative blot is  shown.  [Lanes 1 
and 2 control; 3 and 4 Dex; 5 and 6 LiCl; 7 and 8 Dex and LiCl].  Glucocorticoid causes a decrease in 
prolactin levels.  After a four day treatment with Dex, prolactin levels are practically undetectable  
LiCl treatment also functioned to decrease prolactin levels slightly.   
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DISCUSSION: 
 
The data presented above support the conclusion that glucocorticoid treatment 
directs numerous changes in 235-1 cells.  Previous work in our lab has shown that these 
changes consist of reduced prolactin gene expression, reduced prolactin protein levels, 
decline in the growth rate and decreased cell- to-cell adhesion (Spangler and Delidow, 
1998; Delidow et al., 2002).  The change in cell- to-cell adhesion suggested that there was 
a loss of the cadherin-catenin adhesion complex, although previous research was unable 
to determine which cadherin was responsible in the loss of adhesion.  The catenins are 
partly responsible for the loss of cellular adhesion; however catenin levels are not 
reduced until two days after treatment with Dex, while the loss of adhesion is evident 
immediately because cells start to appear more rounded after one day treatment with Dex.  
We have provided evidence that treatment with glucocorticoid decreases ß-catenin levels 
by increasing at least two different kinase activities, which cause an increase in the 
degradation rate of the protein.   
ß-catenin is a multifunctional protein involved in the regulation of the cadherin-
catenin cell-to-cell adhesion complex and is an important downstream regulator of the 
Wnt signaling pathway.  Experimental data showed that glucocorticoid treatment causes a 
50% reduction in ß-catenin protein levels (Figure 10).  This reduction was due to an 
alteration in the half- life of ß-catenin, without altering the mRNA levels.  ß-catenin’s fate 
in the cytosol is regulated by the presence of Wnt stimulation and phosphorylation. 
Without Wnt signaling, ß-catenin is constantly being phosphorylation by CK1 and 
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GSK3-ß, which targets the protein for degradation.  ß-catenin’s half- life is twenty 
minutes in the 235-1 cells before degradation; however treatment with Dex reduces ß-
catenin’s half- life from twenty to nine minutes.  One hypothesis is that treatment with 
glucocorticoid decreases Wnt stimulation and, therefore, causes a reduction in the 
cytoplasmic ß-catenin levels (Figure 12).   It is also believed that similar effects are 
taking place in the nucleus and membrane.  Membrane-bound ß-catenin is associated in 
the adhesion complex; however glucocorticoid treatment decreases cellular adhesion 
while also decreasing the amount of membrane bound ß-catenin (Figure 12).  This loss of 
ß-catenin from the membrane may be in part responsible for the loss of cellular adhesion 
and the changes in cellular morphology evident in Figure 11.  In the presence of Wnt 
signaling a pool of cytosolic ß-catenin is established, which then translocates ß-catenin to 
the nucleus where it binds to TCF, initiating gene transcription (Provost et al., 2003; 
Chunming et al., 2002).  In the presence of Dex there is a decrease in the amount of 
nuclear ß-catenin, due to the fact that ß-catenin’s degradation has been increased.  
Likewise, there is an increase in the phosphorylated forms of ß-catenin also showing that 
there is an increase in the degradation of ß-catenin (Figure 14BC).   
In the absence of Wnt signaling, GSK3-ß phosphorylates ß-catenin, which then 
forms a complex with the tumor suppressors Axin and adenomatous polyposis coli (APC) 
leading to proteasomal degradation.  Glucocorticoid treatment causes a two-fold increase 
in the amount of active GSK3-ß which phosphorylates ß-catenin (Figure 13B).  When 
Wnt signaling is turned off GSK3-ß activity is turned on and ß-catenin’s translocation to 
the nucleus is decreased.  Our results show that ß-catenin levels are also regulated by the 
inhibition of GSK3-ß.  When GSK3-ß is phosphorylated on Ser 9, the kinase is inactive 
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and will not phosphorylate ß-catenin.  Treatment with glucocorticoid decreased the 
amount of inhibited GSK3-ß by 25% (Figure 13C).   It is believed that both the decrease 
in inhibitory Ser 9 phosphoryla tion and increase in active Tyr 216 phosphorylation of 
GSK3-ß both control the regulation of ß-catenin in the 235-1 cells.  
Abnormalities in Wnt signaling or mutations in the N-terminal phosphorylation 
sites (exon 3) cause an accumulation of cytosolic ß-catenin which initiates gene 
transcription and can ultimately lead to tumorigensis since the whole signaling process is 
up regulated.  The four serine/threonine residues (Ser 33/37/45 and Thr 41) are conserved 
from Drosophilia to human and mutations in these N-terminal phosphorylation sites are 
observed in many types of human tumors (Chunming et al., 2002).  Research has found 
that all such mutations are associated with malignant types of tumors, but there are two 
different mechanisms by which ß-catenin is involved in precipitating colon cancer.  Some 
colon cancer research has found that there is a mutation in the APC complex, while 
others has found mutations in the specific N-terminal phosphorylation sites.  When ß-
catenin is mutated in exon three, it is unable to bind to the F box protein ß-Trcp, which is 
the ubiquitination apparatus (Liu, 2002).  Therefore, ß-catenin accumulates in the cytosol 
eventually turning on gene transcription.         
This work has provided further evidence that there are at least two different 
kinases involved in the phosphorylation of ß-catenin leading to degradation.  When cells 
are treated for a period of four days with Dex and one day with LiCl, there is an increase 
in the amount of phosphorylated ß-catenin.  However, when duplicate cultures are treated 
with Dex and LiC l, our results indicate that Ser 45 phosphorylation is still detectable 
(Figure 14B).  This suggests that Ser 45 is phosphorylated by a kinase other than GSK3-
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ß, since it is not inhibited by LiCl.  Research has shown that in vivo Ser 45 is 
phosphorylated by CK1 and it functions as a priming site on ß-catenin.  When CK1 is 
deleted, ß-catenin is unable to become phosphorylated and ultimately degraded 
(Chunming et al., 2002; Amite et al., 2002).  It has also been found that without CK1 
phosphorylation the GSK3-ß targeted sites are unable to become phosphorylated, which 
can also lead to stabilization of ß-catenin.  This demonstrates the important role of at least 
two different kinases, but also stresses the importance of individual residues in ß-catenin. 
Furthermore, when cells are treated with Dex, there is an increase in Ser 33/37/Thr 41 
phosphorylation.  However, when cells are treated with Dex and LiCl few forms of Ser 
33/37/Thr41 phosphorylated ß-catenin remain (Figure 14C).  These sites are GSK3-ß 
targeted sites and are inhibit ed by LiCl.   These results provide more evidence to support 
the conclusion that two kinases regulate ß-catenin activity. 
A question stemming from this research is how a corticosteroid can activate a 
kinase?  One potential mechanism could be through Akt signaling, which regulates cell 
fate between survival and apoptosis and is also involved in glycogen synthesis.  
Corticosteroids, insulin, and other growth factors have been shown to activate the Akt 
signaling through tyrosine kinases or G-protein coupled receptors (Langdown, 2001; 
Burgering and Coffer,1995; Franke et al., 1995)  Once Akt is activated it can 
phosphorylate a number of substrates involved in inhibiting apoptosis. One such substrate 
phosphorylated by Akt is GSK3-ß (Hajduch et al., 2000; Cross et al., 1995).  GSK3-ß 
regulates ß-catenin’s cellular fate,  is involved in regulating glycogen synthesis in 
response to insulin (Welsh et al., 1996), and is involved in cell cycle regulation by 
preventing phosphorylating of cyclin D1 (Diehl et al., 1998).  If GSK3-ß is 
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phosphorylated by Akt, it demonstrates that cross talk between Wnt signaling and Akt 
signaling exists.  A potential technique to look at the interactions of the two pathways 
would be to block Akt activity to see what alterations occur with GSK3-ß. 
Another area of interest from this research is how CK1 is activated by a 
glucocorticoid?  Our research and others have shown that in order to regulate ß-catenin 
levels, CK1 must be first activated before GSK3-ß can phosphorylate ß-catenin (Amit et 
al., 2002; Chunming et al., 2002).  Additional studies have shown that CK1 appears to 
play a role in glycogen metabolism in response to insulin (Bacskai et al., 1993; Tuazon, 
and Traugh 1991; Osterrieder et al., 1982) and the d isoform of CK1 has been shown in 
vitro to play a role in the hyperphosphorylation of Tau therefore playing a role in 
Alzheimer’s disease (Schwab et al., 2000; Ghoshal et al., 1999).  The possible connection 
is that since GSK3-ß is also involved in these processes then there must be an interaction 
between these two kinases.  However the direct mechanism is unknown.  One reason why 
it is difficult to find out how CK1 and GSK3-ß are related is due to the fact that CK1 
undergoes autoregulation.  This autophosphorylation is main type of regulation for this 
kinase and therefore it is difficult to determine what affects this autophosphorylation or 
what signal activates or inactivates this kinase.         
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CONCLUSIONS: 
In conclus ion, these data suggest that glucocorticoid acts post-translationally to 
alter the level of b-catenin in 235-1 cells by increasing at least two kinase activities.  b-
catenin phosphorylation takes place in two steps: first, it must be primed at Ser 45 by 
CK1; next, b-catenin is phosphorylated by GSK3-b  at Ser 33, 37 and Thr 41, which 
targets the protein for degradation.  Our data show that Dex increases the level of active 
GSK3-b  and decreases the amount of inhibitory GSK3-ß.  The mechanism of increased 
Ser 45 phosphorylation will be the focus of further study to ascertain whether there is an 
alteration in expression or activation of CK1, the putative kinase for this site.  It is 
important to determine the mechanism by which CK1 regulates GSK3-ß activity, since 
Ser 45 must be primed first before GSK3-ß can phosphorylate its targeted sites.  Future 
studies also include looking at the gene targets of ß-catenin to determine whether 
prolactin is one of the targets of expression.     
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